![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » JDS and Synthon Enter Co-Promotion for Lithobid
JDS and Synthon Enter Co-Promotion for Lithobid
JDS Pharmaceuticals and Synthon Pharmaceuticals have entered into a co-promotion agreement for Lithobid (lithium carbonate), a leading brand of twice daily lithium carbonate for the treatment of bipolar disorder. Synthon will co-promote Lithobid through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists. Financial terms of the agreement were not disclosed.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18942420&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct